Welcome to our dedicated page for Innate Pharma SA SEC filings (Ticker: IPHYF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Innate Pharma SA's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Innate Pharma SA's regulatory disclosures and financial reporting.
Innate Pharma S.A. reports that it will host a conference call and live webcast on August 14, 2026 at 2:00 p.m. CEST / 8:00 a.m. EDT. The event will feature CEO Jonathan Dickinson, COO Yannis Morel, CFO Frédéric Lombard and VP Investor Relations Stéphanie Cornen.
The webcast link and telephone registration are provided, and a replay will be available on the company’s website. Innate describes itself as a global, clinical-stage biotechnology company focused on cancer immunotherapies, with a proprietary pipeline centered on antibody-drug conjugates and partnered late-stage assets in cutaneous T-cell lymphomas and non-small cell lung cancer.
Innate Pharma S.A. entered a strategic partnership with Sobi to support development and potential commercialization of lacutamab for cutaneous T‑cell lymphoma. Innate will run the pivotal TELLOMAK‑3 Phase 3 confirmatory trial in Sézary syndrome and mycosis fungoides, targeting a planned accelerated approval filing in Sézary syndrome based on Phase 2 data.
Under the agreement, Sobi will pay USD 75 million on closing, with Innate eligible for up to USD 40 million in near‑term development milestones and up to USD 465 million in additional option, regulatory and commercial milestones, plus tiered double‑digit royalties on net sales. Innate expects the USD 75 million upfront and near‑term milestones to extend its projected cash runway through Q3 2027, funding TELLOMAK‑3 execution and regulatory filings. Sobi gains exclusive global commercialization rights after potential accelerated approval and may assume full global development rights following positive Phase 3 results. Innate also appointed Markus Jensen as Chief Medical Officer effective September 1, 2026, providing leadership continuity for lacutamab, IPH4502 and monalizumab. Closing of the transaction is subject to customary conditions, including anti‑trust clearance.
Innate Pharma S.A., a clinical-stage biotechnology company developing immunotherapies for cancer patients, announced that its EVP Chief Medical Officer, Sonia Quaratino, will join the bladder cancer panel Changing Treatment Landscape in Bladder Cancer at the BTIG Virtual Biotechnology Conference 2026.
The panel is scheduled for July 28, 2026 at 10:30 a.m. EDT / 4:30 p.m. CEST. Innate Pharma highlights a pipeline of antibody-based therapies, including IPH4502 for solid tumors, lacutamab for cutaneous T cell lymphomas, and monalizumab for non-small cell lung cancer, developed in collaboration with AstraZeneca.
Innate Pharma S.A., a clinical-stage biotechnology company, reports completion of enrollment in the dose-escalation part of its Phase 1 IPH4502-101 study of IPH4502, a proprietary Nectin-4 exatecan antibody-drug conjugate, with 76 patients enrolled in France and the United States.
The study evaluates safety, tolerability and preliminary anti-tumor activity in patients with advanced solid tumors known to express Nectin-4. The company states that IPH4502 continues to show a favorable safety profile with limited hematological toxicity and ongoing preliminary objective responses in urothelial carcinoma post enfortumab vedotin, non-small cell lung cancer and head and neck squamous cell carcinoma. Preliminary data from the dose escalation are expected by year-end to guide Phase 1 dose optimization.
Innate Pharma SA disclosure: Novo Nordisk A/S filed Schedule 13G/A (Amendment No. 4) reporting 0 shares beneficially owned representing 0.00% of Innate Pharma's ordinary shares. The amendment is signed by Karsten Munk Knudsen, Chief Financial Officer, on 06/22/2026.
Innate Pharma S.A. reported the results of its 2026 Annual General Meeting held in Marseille on May 21, 2026. All resolutions were voted, with a total of 94 votes cast out of 34,872,293 shares representing 34,921,313 voting rights, corresponding to a 37,136% quorum.
The detailed resolutions, voting results, related documents and an AGM recording will be provided in the 2026 Annual General Meeting section of the company’s website. Innate Pharma is a clinical-stage biotechnology company developing next-generation antibody-based immunotherapies for cancer, with collaborations including AstraZeneca and Sanofi.
Innate Pharma S.A., a clinical-stage biotechnology company focused on cancer immunotherapies, filed a Form 6-K to share that its executive team will participate in one-on-one investor meetings at the Jefferies Global Healthcare Conference 2026 in New York from June 2–4, 2026.
The company highlights its pipeline of potential first- or best-in-class antibody-based therapies, including IPH4502 for solid tumors, lacutamab for T-cell lymphomas, and monalizumab, which is being developed with AstraZeneca for non-small cell lung cancer. Innate also notes broader collaborations with partners such as Sanofi and AstraZeneca and its listings on Euronext Paris and Nasdaq.
Innate Pharma reported its latest business update and financial position alongside full-year 2025 results. The company is preparing the TELLOMAK-3 confirmatory Phase 3 trial for lacutamab in cutaneous T‑cell lymphomas in H2 2026, contingent on non-dilutive financing such as pharma partnering and royalty deals now under negotiation.
IPH4502, a Nectin-4 ADC, reached its maximum tolerated dose in Phase 1 with preliminary anti-tumor activity and a favorable safety profile, while AstraZeneca-led PACIFIC‑9 and the MATISSE Phase 2 study for IPH5201 continue to advance in non-small cell lung cancer. Cash, cash equivalents and financial assets totaled €25.4 million as of March 31, 2026, providing an expected cash runway until the end of Q3 2026, and Q1 2026 revenue was €2.6 million, primarily from AstraZeneca and Sanofi collaborations.
Innate Pharma S.A. reports its capital and voting structure as of April 16, 2026. The company has 93,934,210 shares outstanding, made up of 93,921,863 ordinary shares, 4,766 Preferred Shares 2016 and 7,581 Preferred Shares 2017. The total number of theoretical voting rights is 93,921,863, while exercisable voting rights, excluding treasury shares with suspended rights, total 93,903,288.
Innate Pharma S.A. filed a Form 6-K to share a press release announcing a conference call and webcast to discuss its business progress for the first quarter of 2026. The call will take place on Wednesday, May 13, 2026 at 1:30 p.m. CEST / 7:30 a.m. EDT.
Management participants will include the Chief Executive Officer, Chief Medical Officer, Chief Operating Officer, Head of Investor Relations, and Chief Financial Officer. The event will be accessible via webcast and telephone, with a replay available on the company’s website for 90 days.
The release also briefly describes Innate Pharma as a global, clinical-stage biotechnology company focused on cancer immunotherapies, highlighting key programs such as IPH4502, lacutamab and monalizumab, and noting collaborations with partners including AstraZeneca and Sanofi.